Communiqués Silexion Therapeutics Corp

Actions

SLXN

KYG1281K1489

Recherche biotechnologique et médicale

Cours en clôture Nasdaq 14/08/2026			Varia. 5j.	Varia. 1 janv.
0,4202 ^USD	-8,65%		-77,53%	-97,81%

14/08	Silexion Therapeutics Corp publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/08	Les plus fortes baisses de l'avant-bourse	MT

Communiqués

14/08	Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
12/08	Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering	AQ
04/08	Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers	AQ
29/07	Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center	AQ
23/06	Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer	AQ
16/06	Silexion Therapeutics to Attend BIO International Convention 2026	AQ
26/05	Silexion Therapeutics Announces 1-for-10 Reverse Share Split	AQ
18/05	Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
15/05	Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds	AQ
14/05	Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer	AQ
13/05	Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center	AQ
28/04	Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer	AQ
24/03	Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer	AQ
17/03	Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
05/03	Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting	AQ
03/02	Silexion Therapeutics : Corporate Presentation -February 2025	PU
21/01	Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit	AQ
06/01	Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026	AQ
16/12	Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer	AQ
02/12	Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer	AQ
02/12	Silexion Therapeutics : Corporate Presentation – November 2025	PU
26/11	Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference	AQ
25/11	Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer	AQ
12/11	Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
30/09/25	Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer	AQ